Last reviewed · How we verify
Dopamine Agent
A dopamine agent enhances dopaminergic neurotransmission by increasing dopamine availability or receptor activation in the central nervous system.
A dopamine agent enhances dopaminergic neurotransmission by increasing dopamine availability or receptor activation in the central nervous system. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | Dopamine Agent |
|---|---|
| Also known as | Dopaminergic drugs |
| Sponsor | I.R.C.C.S. Fondazione Santa Lucia |
| Drug class | Dopamine agonist or dopamine enhancer |
| Target | Dopamine receptors (D1-D5) or dopamine transporter |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Dopamine agents work by either increasing dopamine synthesis, blocking its reuptake, or directly activating dopamine receptors. This enhances dopaminergic signaling, which is critical for motor control, motivation, and reward processing. Such agents are commonly used to treat conditions characterized by dopamine deficiency or dysfunction.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Orthostatic hypotension
- Dyskinesia
- Hallucinations
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Diagnosis of Pheochromocytoma (PHASE1)
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Blinking and Yawning in Epilepsy: The Role of Dopamine (NA)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
- Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
- Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dopamine Agent CI brief — competitive landscape report
- Dopamine Agent updates RSS · CI watch RSS
- I.R.C.C.S. Fondazione Santa Lucia portfolio CI